HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation

BACKGROUND: Paclitaxel is a first-line chemotherapy drug for pancreatic, ovarian, endometrial cancers and other malignancies. However, its efficacy is often compromised by decreased cell sensitivity or the development of resistance. Human epididymis protein 4 (HE4) is highly expressed in gynecologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Fengbiao, Li, Jinping, Qi, Yaozhi, Hou, Jianqing, Chen, Haibin, Jiang, Shi-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218645/
https://www.ncbi.nlm.nih.gov/pubmed/32435154
http://dx.doi.org/10.1186/s12935-020-01248-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218645/
https://www.ncbi.nlm.nih.gov/pubmed/32435154
http://dx.doi.org/10.1186/s12935-020-01248-1

Ejemplares similares